We’re Closer Than Ever To Beating Alzheimer’s. Price Controls Could Change That.

We’re Closer Than Ever To Beating Alzheimer’s. Price Controls Could Change That.

Earlier this month, the U.S. Food and Drug Administration approved donanemab, a novel treatment for Alzheimer’s disease that Eli Lilly will sell under the brand name Kisunla.

The drug targets amyloid, a type of protein that builds up in the brains of people with the disease. It was shown to slow the progression of Alzheimer’s by 35% over 18 months compared to a placebo.

Donanemab’s approval comes about a year after the agency gave the green light to lecanemab, another monoclonal antibody proven to slow the progression of Alzheimer’s. Eisai and Biogen are marketing it as Leqembi.

Click to read the full article in Forbes.